INKT - NASDAQ

MiNK Therapeutics, Inc.

INKT·NASDAQ

$12.76

+1.4%

HealthcareBiotechnology

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$63.57M

EPS-2.9300

P/E Ratio-4.35

Earnings Date08/12/2026

inkt

Short Term Debt

Last Annual Value

5.18M

3-Year CAGR

5-Year CAGR

10-Year CAGR

Adjust for Inflation

MiNK Therapeutics, Inc. Competitors Analysis of Short Term Debt

INKT · NASDAQ

Company	Short Term Debt	CAGR 3Y	CAGR 5Y	CAGR 10Y
MiNK Therapeutics, Inc. NASDAQ:INKT	5.18M	N/A	N/A	N/A
Equillium, Inc. NASDAQ:EQ	363.00K	N/A	-24.0%	N/A
Werewolf Therapeutics, Inc. NASDAQ:HOWL	1.75M	-36.0%	N/A	N/A
Outlook Therapeutics, Inc. NASDAQ:OTLK	58.90B	1083.3%	817.8%	154.3%
BeyondSpring Inc. NASDAQ:BYSI	320.00K	7.4%	-27.2%	4.3%
Precision BioSciences, Inc. NASDAQ:DTIL	1.51M	-59.3%	N/A	N/A
Estrella Immunopharma, Inc. NASDAQ:ESLA	0.00	N/A	N/A	N/A
Relmada Therapeutics, Inc. NASDAQ:RLMD	0.00	N/A	N/A	N/A
Cue Biopharma, Inc. NASDAQ:CUE	0.00	N/A	N/A	N/A
MediciNova, Inc. NASDAQ:MNOV	194.33K	N/A	N/A	N/A
NRx Pharmaceuticals, Inc. NASDAQ:NRXP	316.00K	-67.4%	-9.4%	N/A

MiNK Therapeutics, Inc. Fair Value Envelope

INKT · NASDAQ

Our analysis suggests that INKT has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $12.76, this represents a potential HIDDEN relative to our calculated worth for MiNK Therapeutics, Inc..

HIDDEN

Intrinsic Value

Current Price: $12.76

Related Guides

Blog Categories

Continue your INKT research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.